MGRX
Mangoceuticals, Inc.
Set alert
0.23 USD -0.02 -8.22%
0.2292 Day range 0.2595
0.162 52-week range 2.21
- YTD
- -68.46%
- 1 year
- -88.61%
- Open
- 0.257
- Prev close
- 0.2543
- Mkt cap
- 5.19M
- Vol
- 531.82K
- Avg vol
- 11.53M
- EPS
- -1.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2292
- High
- 0.2595
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.21
- Inst. own
- 4.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.49
- 200-d avg
- 3.94
- 1y target
- 0.00
Key statistics
- Market cap
- 6.17M
- Enterprise value
- 4.40M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 4.57
- EPS (TTM)
- -5.70
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 866.79K
- Revenue growth
- 15.50%
- Free cash flow
- -2.16M
- Total cash
- 490.24K
- Total debt
- 285.05K
- Return on equity
- -108.44%
- Shares outstanding
- 2.49M
- Short % of float
- 9.99%
- 50-day average
- 2.49
- 200-day average
- 3.94
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MGRX Revenue — quarterly 68.76K
MGRX Net income — quarterly -1.31M
MGRX EPS — quarterly -0.09
About Mangoceuticals, Inc.
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- mangoceuticals.com
News
- Analyzing Mangoceuticals (NASDAQ:MGRX) & Quest Diagnostics (NYSE:DGX)
- Mangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrants
- Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercialization
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
- Stock Market Today: S&P 500, Dow Jones Futures Gain as September Jobs Report Misses Expectations— Nike, Synaptics, Corteva in Focus (UPDATED)
- Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Nike, Synaptics And 3 Stocks To Watch Heading Into Friday
- Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why
- Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche
Your note
Sign in to keep a note on MGRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN JACOB D. | Chief Executive Officer | Stock Gift | Aug 25, 2024 | 0 |
| D'ALESSIO LORRAINE PAMELA | Director | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
| HAMILTON ALEX P | Director | Sale | Jun 25, 2024 | 50,000 |
| HAMMER AMANDA ELIZABETH | Chief Operating Officer | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
| JOHNSTON EUGENE M | Chief Financial Officer | Stock Award(Grant) | Oct 2, 2023 | 200,000 |
| MYERS KENNY | Director | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ackerman Capital Advisors, LLC | 2.34% | 58,224 | 144.40K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.69% | 17,077 | 42.35K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 8,755 | 21.71K | Sep 29, 2024 |
| Peak6 Investments Llc | 0.24% | 5,884 | 14.59K | Sep 29, 2024 |
| McCollum Christoferson Group LLC | 0.23% | 5,720 | 14.19K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 2,523 | 6.26K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.27% | 6,603 | 16.38K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 3,245 | 8.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,577 | 3.91K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 452 | 1.12K | Oct 30, 2024 |